Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

Recent News and Articles on the Keywords: stent + stents + heart  Related to the article below (Last Update: 8/5/2008)

Johnson & Johnson Receives Subpoena on Bile Duct Stents New York Times, United States - By BLOOMBERG NEWS Johnson & Johnson said on Monday that it had been subpoenaed by the Justice Department in connection with its sales of bile duct stents, ... J&J Receives US Subpoena Over Bile Duct Stent Sales (Update3) Bloomberg UPDATE: US DOJ Probing Marketing For Bile-Duct Stents CNNMoney.com J&J Receives Subpoena Over Stents Wall Street Journal Reuters - Bloomberg all 8 news articles »  JNJ - BSX - ABT Business Topics by Industry Sun-Sentinel.com, FL - Johnson & Johnson said it was subpoenaed by the US Justice Department for information on the marketing of bile duct stents made by its Cordis subsidiary. ...ROH - BLG - DOW Fitch cuts Abbott Labs rating, raises outlook Forbes, NY - s stent business and Kos Pharmaceuticals. In the past, Abbott has made large acquisitions every two to three years, but has rapidly cut down its debt after ... Fitch Downgrades Abbott Laboratories' IDR to 'A+'; Outlook to Stable MarketWatch all 23 news articles »  ABT ANALYSIS-Unilever overdoes pricing as volumes slide Reuters India, India - Not in our opinion," said industry analyst Jeff Stent at brokers Citi. "This is not the return of Path to Growth, but we do see Q2 as a signal that life for ...UL - UN RTT News Boston Sci Backs Full-Year Outlook, Sets 3Q Stent Goals CNNMoney.com - Jul 22, 2008 (BSX) on Tuesday affirmed its full-year sales and earnings guidance, and also set targets for coated stent sales in the third quarter, when it will receive ... Boston Scientific Net Falls, Hurt by Charges, Stent Sales Wall Street Journal Boston Sci stock hits 6-year low Minneapolis Star Tribune Leaner Boston Scientific Isn't Looking Healthy Motley Fool guardian.co.uk - CNNMoney.com all 63 news articles »  BSX - S - STJ Business Wire (press release) Cook Medical Receives FDA Approval to Market Improved Zenith? AAA ... Business Wire (press release), CA - The Zenith AAA Flex Leg external stents are shorter than those of Cook Medical?s previous offering, with increased gaps between the stents. ... Medtronic Starts US Arm of Global Stent Study FDA news (subscription), VA - Aug 1, 2008 Medtronic has begun enrolling patients for US sites in its PROTECT study, a global trial comparing the safety of its Endeavor drug-eluting stent with ...MDT - JNJ Medtronic initiates US arm of drug-eluting stent trial Trading Markets (press release), CA - Aug 1, 2008 Protect sites in the US will serve to provide the FDA with US-specific data on the post-market experience with the Endeavor stent. The US sites will enroll ...MDT - OTC:CMTX MIV Therapeutics' CEO Mark Landy Joins Distinguished Leaders ... MarketWatch - Jul 29, 2008 The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. ... MIV Therapeutics? CEO Mark Landy Joins Distinguished Leaders ... Business Wire (press release) all 23 news articles »  OTC:MIVI Multidetector computed tomography angiography for assessment of in ... 7thSpace Interactive (press release), NY - Jul 31, 2008 The proportion of non-assessable stents was influenced by the number of detectors, stent diameter, strut thickness and the use of an edge-enhancing kernel. ...

Bare-metal stents are better for some heart patients

(PHILADELPHIA) -- While drug-eluting stents are effective in keeping open diseased heart arteries, they should not be used for patients who need to have non-cardiac surgery a short time after an interventional heart procedure. A presentation at the Society for Cardiovascular Angiography and Interventions in Orlando by cardiologists at Jefferson Medical College indicates that for these patients, bare metal stents provide a safer choice.

"The issue here," says Michael Savage, M.D., Catheterization Laboratory Director at Thomas Jefferson University Hospital in Philadelphia, "is that studies have demonstrated that those patients who receive drug-eluting stents may develop life-threatening cardiac complications if they undergo subsequent, non-cardiac surgery."

This prescription for the potentially deadly problem begins when a person, often a senior citizen, learns that she or he must have elective surgery. The surgery can be for a minor to a major problem--from vacular surgery to fix blood flow problems, to broken hips or bones, neurological or urological issues and more.

Article continues below and (thank you)

Often, severe coronary artery disease is discovered during the pre-surgical testing. If severe, it presents a more-immediate problem and therefore, must be treated before the patient undergoes the elective surgery.

Prior studies have shown that patients may suffer fatal heart attacks due to clotting inside of the stents when surgery is performed within a few weeks after stent placement. In the case of drug-eluting stents, clotting of the stent may occur even months or years after their heart procedure, particularly when their blood thinning medicine (usually aspirin and Plavix) are stopped before the surgery.

To avoid the potentially deadly scenario, the Jefferson Medical College researchers developed a clinical protocol to enable patients to have both procedures successfully with little risk. Led by Agostino Ingraldi, M.D., a fellow in cardiovascular diseases, they developed the following four-part strategy:

• Avoidance of drug-eluting stents in favor of bare metal stents during the interventional heart procedure.
• A four-week course of the blood thinner clopidogrel (Plavix) after an interventional heart procedure.
• Deferral of the second, non-cardiac surgery for five to 12 weeks after the interventional procedure.
• Discontinuation of clopidogrel (Plavix) at least five days prior to the non-cardiac surgery.

The researchers studied a total of 60 patients (33 men and 27 women) who averaged 68 years old and who were treated with the strategy. Twenty seven percent suffered from diabetes which can complicate surgery.

The results show the coronary interventional procedure was successful in all patients where a total of 82 heart lesions were treated with bare-metal stents. The second, non-cardiac, surgery was performed an average of 47 days later. All were performed under general anesthesia and were successful. There were no deaths or clotting leading to problems. Also, clotting of the stents--a major problem seen with drug-eluting stents in this setting--were not seen in any patient.

"This research provides a safe treatment strategy for interventional cardiologists and their patients who will be undergoing further surgery," adds Dr. Savage, who is also associate professor of Medicine, Jefferson Medical College of Thomas Jefferson University. "Drug-eluting stents have proven benefits but may not be the best solution for every patient."

Editor’s Note: Members of the team who conducted this study at Thomas Jefferson University Hospital in Philadelphia, Pa., are:

• Agostino Ingraldi, M.D., Nicholas J. Ruggiero II, M.D., Mark Awar, M.D.,
• Saum Shamimi-Noori, M.D., Utpal Sager, M.D., David Fischman, M.D.,
• Paul Walinsky, M.D., Howard H. Weitz, M.D., and Michael Savage, M.D.